7 results match your criteria: "Department of Clinical Pharmacology and Neuroscience[Affiliation]"
Motivational and cognitive predictors of apathy after subthalamic nucleus stimulation in Parkinson's disease.
Brain
February 2024
Service de Neurologie, NS-Park/F-CRIN network, Hôpitaux Universitaires de Strasbourg et Fédération de Médecine Translationnelle de Médecine de Strasbourg, 67200 Strasbourg, France.
Postoperative apathy is a frequent symptom in Parkinson's disease patients who have undergone bilateral deep brain stimulation of the subthalamic nucleus. Two main hypotheses for postoperative apathy have been suggested: (i) dopaminergic withdrawal syndrome relative to postoperative dopaminergic drug tapering; and (ii) direct effect of chronic stimulation of the subthalamic nucleus. The primary objective of our study was to describe preoperative and 1-year postoperative apathy in Parkinson's disease patients who underwent chronic bilateral deep brain stimulation of the subthalamic nucleus.
View Article and Find Full Text PDFHeterogeneity of PD-MCI in Candidates to Subthalamic Deep Brain Stimulation: Associated Cortical and Subcortical Modifications.
J Parkinsons Dis
July 2022
Univ. Lille, Inserm, Lille Neurosciences and Cognition, CHU-Lille, Neurology and Movement Disorders department, NS-Park/F-CRIN, Lille, France.
Background: Parkinson's disease mild cognitive impairment (PD-MCI) is frequent and heterogenous. There is no consensus about its influence on subthalamic deep brain stimulation (STN-DBS) outcomes.
Objective: To determine the prevalence of PD-MCI and its subtypes in candidates to STN-DBS.
Preoperative REM Sleep Behavior Disorder and Subthalamic Nucleus Deep Brain Stimulation Outcome in Parkinson Disease 1 Year After Surgery.
Neurology
November 2021
From the Neurology Department, Université Clermont Auvergne, EA7280 (E.B.-P., F.D., M.L.F., E.D., B.D., P.D., A.M.), and Biostatistics Department (B.P.), Clermont-Ferrand University Hospital, NS-Park/F-CRIN Network; Departments of Medical Pharmacology and Neurology and Movement Disorders, Referent Center of Parkinson's Disease, INSERM UMRS_1171, Licend, CHU of Lille (C.M.), and Department of Medical Pharmacology, University Hospital, Lille Neuroscience & Cognition, INSERM, UMR-S1172 (A.-S.R., D.D.), University of Lille, NS-Park/F-CRIN Network; Department of Neurology, Paris Brain Institute (ICM) (E.H., J.-C.C.), Institut Du Cerveau, INSERM CNRS, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Hôpital Pitié-Salpêtrière, NS-Park/F-CRIN Network; Department of Neurology (T.R.), Nantes University Hospital, NS-Park/F-CRIN Network; Department of Neurology (A.E.), Assistance Publique Hôpitaux de Marseille, Timone University Hospital and Institut de Neurosciences de La Timone, NS-Park/F-CRIN Network; Department of Neurology (I.B.), University Poitiers, NS-Park/F-CRIN Network; Department of Neurology (S.D.), University Hospital of Rennes, NS-Park/F-CRIN Network; Institut des Maladies Neurodégénératives, Centre Expert Parkinson (D.G.), CHU de Bordeaux, NS-Park/F-CRIN Network; Parkinson Expert Center, Department of Clinical Pharmacology and Neuroscience (O.R.), Clinical Investigation Center CIC1436, NeuroToul COEN Center, Toulouse University Hospital, University of Toulouse 3, INSERM, NS-Park/F-CRIN Network; Department of Neurology (D.M.), Rouen University Hospital and University of Rouen; Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (D.M.), INSERM U1239, NS-Park/F-CRIN Network, Mont-Saint-Aignan; Department of Neurology (O.L.-B.), Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, NS-Park/F-CRIN Network; Department of Neurology (C.G.), Centre Hospitalier Universitaire de Nice, NS-Park/F-CRIN Network; Departments of Neurology and Neurosurgery (M.T.), Expert Centre for Parkinson's Disease, EA 4559 Laboratoire de Neurosciences Fonctionnelles et Pathologie, Amiens University Hospital, Université de Picardie Jules Verne, NS-Park/F-CRIN Network, Amiens; Department of Neurology C (S.T.), Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, University Hospital of Lyon, Université Claude Bernard Lyon 1, CNRS, Institut des Sciences Cognitives Marc Jeannerod, UMR 5229 CNRS, NS-PARK/F-CRIN Network; Department of Neurology (L.H.), University Hospital of Nancy, NS-PARK/F-CRIN Network; Department of Neurology (C.H.), Hospital Fondation Ophtalmologique Adolphe de Rothschild, NS-PARK/F-CRIN Network; and Neuroscience Pole (B.J.), Hôpital Foch, Université Paris-Saclay (UVSQ), INSERM-CEA NeuroSpin, NS-PARK/F-CRIN Network, Paris, France.
Background And Objectives: To determine whether patients with Parkinson disease (PD) eligible for subthalamic nucleus deep brain stimulation (STN-DBS) with probable REM sleep behavior disorder (RBD) preoperatively could be more at risk of poorer motor, nonmotor, and quality of life outcomes 12 months after surgery compared to those without RBD.
Methods: We analyzed the preoperative clinical profile of 448 patients with PD from a French multicentric prospective study (PREDISTIM) according to the presence or absence of probable RBD based on the RBD Single Question and RBD Screening Questionnaire. Among the 215 patients with PD with 12 months of follow-up after STN-DBS, we compared motor, cognitive, psycho-behavioral profile, and quality of life outcomes in patients with (pre-opRBD+) or without (pre-opRBD-) probable RBD preoperatively.
On-Demand Therapy for OFF Episodes in Parkinson's Disease.
Mov Disord
October 2021
University and Institute for Research and Medical Care, IRCCS San Raffaele Pisana, Rome, Italy.
Levodopa is the most effective therapy for Parkinson's disease; however, chronic treatment is associated with the development of OFF episodes, in which there is a return of parkinsonian features following a dose of levodopa and prior to the onset of benefit from the subsequent dose. OFF episodes can be a major source of disability for PD patients and frequently result in depression, apathy and an unwillingness to participate in social activities. Most currently available medical and surgical therapies are designed to reduce total daily OFF time but do not provide a rapid and reliable "on-demand" therapy for individual OFF episodes.
View Article and Find Full Text PDFImpact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study.
Mov Disord
March 2021
Department of Neurology, NS-PARK/F-CRIN, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Médecine de Strasbourg, Strasbourg, France.
Background: Impact of subthalamic deep brain stimulation (DBS) on impulse control disorders (ICD) in Parkinson's disease (PD) remains controversial.
Objectives: The objectives of this study were to analyze the natural history of ICD between baseline and 1 year after subthalamic DBS in patients with PD and to identify predictive factors, taking into account the positions of the active contact and stimulation parameters.
Methods: We analyzed postoperative modifications of ICD based on the multicentric, prospective Predictive Factors and Subthalamic Stimulation in Parkinson's Disease cohort.
Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study.
Parkinsonism Relat Disord
February 2020
Acorda Therapeutics, Inc., Ardsley, NY, USA.
Introduction: CVT-301 is an orally inhaled levodopa therapy approved for the intermittent treatment of OFF episodes in Parkinson's disease patients who are taking a standard oral levodopa regimen. This open-label, randomized, controlled study over 12 months characterizes the safety, including pulmonary safety, of CVT-301 84 mg (nominal respirable levodopa fine-particle dose, 50 mg).
Methods: Patients experiencing motor fluctuations were randomized 2:1 to CVT-301 or an observational cohort (OC) receiving oral standard of care.
Emerging drugs for autonomic dysfunction in Parkinson's disease.
Expert Opin Emerg Drugs
March 2013
University of Toulouse III, University Hospital, Department of Clinical Pharmacology and Neuroscience, Toulouse, France.
Introduction: Autonomic dysfunction, including orthostatic hypotension (OH), sialorrhea, sexual dysfunction, urinary dysfunction and constipation is a common feature of Parkinson's disease (PD). Even though its treatment has been recognized as a major unmet need in PD, there is a paucity of clinical trials to assess their treatment.
Areas Covered: Evidence about the efficacy and safety of available treatments for autonomic dysfunction is summarized.